AdvaMed Names Brian J. Blaser, QuidelOrtho President and CEO, Chair of AdvaMedDx Board of Directors  

WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced that Brian Blaser, president and CEO of QuidelOrtho, will serve as the next chair of the AdvaMedDx Division Board of Directors, succeeding Thierry Bernard, CEO of QIAGEN. AdvaMedDx represents more than 70 manufacturers of the innovative in vitro diagnostic (IVD) tests critical to patient care. 

“Diagnostic tests are essential to timely diagnoses and appropriate patient care,” said Scott Whitaker, AdvaMed president and CEO. “The AdvaMedDx division drives the advocacy necessary to ensure patients have full access to the range of tests available to diagnose illness quickly and precisely and inform the right course of treatment. Congratulations and thank you to Brian for his willingness to lead AdvaMed’s work in this vital field, and thank you to Thierry for his exemplary service over an extended term as AdvaMedDx board chair.” 

Blaser will lead the AdvaMedDx division board at a pivotal time for the diagnostics industry, as advances in molecular testing, artificial intelligence, and point-of-care technologies continue to transform how diseases are detected and monitored. 

“I’m honored to serve as AdvaMedDx board chair and to work alongside the division’s member companies to advance our shared priorities,” said Blaser. “I’m also committed to advancing a regulatory landscape that keeps pace with innovation and reimbursement policies enabling patient care.” 

“AdvaMedDx is fortunate to represent the leading in vitro diagnostic test makers,” said Zach Rothstein, executive director of AdvaMedDx. “Our division reflects the expertise and vision of those creating the tests that influence 70 percent of all health care decisions. Brian and Thierry understand the essential role in vitro diagnostic tests play in medical care around the clock, and their leadership is vital to sustaining this critical, scientifically rigorous facet of our health care system.” 

Blaser will serve a two-year term beginning this month.  

###